Intel stock extends gains after report of possible U.S. government stake
Michael H. Finger, a director at Creative Medical (TASE:BLWV) Technology Holdings, Inc. (NASDAQ:CELZ), recently executed sales of the company’s common stock, according to a filing with the Securities and Exchange Commission. The micro-cap company, currently valued at $8.29 million, has seen its stock surge over 88% in the past six months and 26% in the last week alone. The transactions, conducted on February 18 and 19, involved the sale of a total of 1,500 shares. The shares were sold at prices ranging from $5.00 to $5.75 per share, yielding a total value of $8,062. Following these transactions, Finger retains ownership of 351 shares in the company. According to InvestingPro analysis, the stock’s technical indicators suggest it’s currently in overbought territory, though management has been actively buying back shares. Get access to 13 more exclusive InvestingPro Tips for CELZ to make more informed investment decisions.
In other recent news, Creative Medical Technology Holdings, Inc. reported promising results from its AlloStem™ Type 2 Diabetes pilot study, demonstrating an 80% efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels without serious adverse effects. This study involved 20 participants and confirmed the safety and efficacy of the CELZ-201 treatment. Additionally, Creative Medical announced a strategic collaboration with Greenstone Biosciences Inc. to employ Artificial Intelligence in advancing its stem cell platform for diabetes treatment. This partnership aims to enhance the function of hypoimmune induced pluripotent stem cell (iPSC) technology and reduce the need for immunosuppression in treatments.
In a separate development, Creative Medical amended its Articles of Incorporation to increase the number of authorized shares of common stock from 5 million to 25 million, following approval from its stockholders. The company also withdrew certificates of designation for Series A and Series B Preferred Stock, with no outstanding shares of either series. Furthermore, stockholders approved the full exercise of warrants to purchase 837,104 shares of common stock, initially issued in a private placement. These changes reflect the company’s ongoing efforts to expand its capabilities and resources in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.